12 Best Short Squeeze Stocks to Buy Right Now

Page 8 of 12

5. Immunovant, Inc. (NASDAQ:IMVT)

short % of float: 22.01%

Number of Hedge Fund Holders: 40

Immunovant, Inc. (NASDAQ:IMVT) ranks among the best short squeeze stocks to buy right now. Following the company’s fiscal second-quarter 2026 financial results, Oppenheimer reaffirmed its Outperform rating on Immunovant, Inc. (NASDAQ:IMVT) on November 11 with a price target of $54. The company’s reported earnings per share of -$0.73 fell short of the -$0.71 consensus estimate. With $4.4 billion in cash and no debt on its balance sheet, Immunovant, Inc. (NASDAQ:IMVT) maintains a strong capital position in despite these deficits.

The company intends to publish results from a proof-of-concept study in cutaneous lupus and preliminary clinical data for IMVT-1402 in ACPA+ difficult-to-treat rheumatoid arthritis in 2026. According to Oppenheimer, the medication is “positioned as best-in-class” and has “considerable upside” as it moves closer to possible commercialization across multiple indications.

Immunovant, Inc. (NASDAQ:IMVT) is also testing a second drug candidate, batoclimab, in mid-late-stage trials for two separate autoimmune conditions: GD and thyroid eye disease (TED).

Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage immunology company focused on developing innovative therapies for autoimmune diseases. The company’s primary focus is on creating anti-FcRn (neonatal Fc receptor) antibodies which aim to reduce harmful immunoglobulin G (IgG) autoantibodies in patients with various autoimmune conditions.

Page 8 of 12